Learn More
There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These include N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (PK1, FCE28068), HPMA copolymer-paclitaxel (PNU 166945), HPMA copolymer-camptothecin, PEG-camptothecin, polyglutamic acid-paclitaxel, an HPMA copolymer-platinate(More)
city and the appearance of multidrug resistance. Improvements, particularly for the treatment of common solid tumours, have been difficult to realise (Connors, 1996) and as a result combination therapies designed to increase active drug concentration in the tumour have been developed; namely antibody-directed enzyme prodrug therapy (ADEPT) (Bagshawe, 1987;(More)
Polymer-directed enzyme prodrug therapy (PDEPT) is a novel two-step antitumour approach using a combination of a polymeric prodrug and polymer-enzyme conjugate to generate cytotoxic drug selectively at the tumour site. In this study the polymeric prodrug N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-Gly-Phe-Leu-Gly-doxorubicin conjugate PK1 (currently(More)
Article history: Keywords: Negative word-of mouth (WOM) Secondary information Online diffusion of information Electronic word-of-mouth (eWOM) a b s t r a c t The purpose of this research is to investigate negativity bias in secondary electronic word-of-mouth (eWOM). Two experiments, one laboratory and one field, were conducted to study actual dissemination(More)
  • 1